Who We Are
- Leadership Team
- Board of Directors
Our Platform
- Posters & Publications
Our Pipeline
- Inflammatory Diseases
Patients, Families & Physicians
Investors & Media

Careers
Contact Us

Skip to main content
Skip to footer

Discover how Evelo’s EDP1815 may prevent the progression of COVID-19. Learn More

Evelo

A phase I/II clinical trial of EDP1503 with pembrolizumab for triple-negative breast cancer

Home/Posters/A phase I/II clinical trial of EDP1503 with pembrolizumab for triple-negative breast cancer

December 11, 2020 by

Footer

Terms of Use/Privacy Policy

© Evelo Biosciences, Inc.
EVELO is a registered U.S. trademark of Evelo Biosciences, Inc.

Follow Us LinkedIn